

BUILD & CONDUCT ANXIETY RESEARCH WITH WORLD-RENOWNED CNS EXPERTS

Generalized anxiety disorder (GAD) is a leading cause of patient suffering and disability around the world, so there is a continued need to develop new, effective treatments and therapeutic options. At Signant, we offer sponsors a team with scientific expertise and global experience, alongside our innovative clinical technology, to help them run successful GAD studies. Leverage our Signant SmartSignals suite to help your adult or pediatric GAD study succeed.



Optimize the Participant Education Experience

Signant's robust eConsent platform employs multimedia, managed interactions, content flagging, and virtual visits to ensure participant comprehension of your protocol requirements, no matter how complex, while improving the site and participant experience. Plus, automated version control ensures the presentation of only the most recently approved ICD versions, thus eliminating common FDA audit findings.



Simplify Assessments & Adherence for Participants

Patient-reported outcome measures (PROMs) are vital to fully evaluate GAD treatment risk-benefit profiles. Our eCOA solution can be tailored to your protocol and participant population's needs – guided assessments and built-in edit checks reduce errors, while alerts and reminders improve adherence to medication dosing and assessment schedules.



Manage Rater Quality to Improve Data Reliability

Train and monitor raters to ensure consistency and accuracy with our Rater Training & Qualification and Central Review services. Our experts ensure raters score and administer GAD assessments correctly as well as adhere to eligibility criteria and study protocols. We also mitigate excessive placebo response and expectation bias by providing independent reviews or scoring of diagnostic and efficacy measures.



Monitor Study Data as They Flow In

Our unique PureSignal Analytics solution leverages proprietary algorithms to evaluate clinical outcome assessment data at all levels in real-time. Expert clinicians analyze outliers, anomalies or discrepancies that could indicate quality risks, and deliver appropriate interventions. By proactively safeguarding endpoint data reliability throughout study lifecycle, the solution helps optimize signal detection.



Maximize Signal Detection Opportunities

Talk through your GAD protocol with our science and medicine experts, who can serve as an extension of your study team. We guide the selection and acquisition of endpoints and assessments, advise on inclusion/exclusion criteria, and recommend methods to decrease site and participant burdens while improving data quality.



Digitalize the Entire Process

While all of our solutions can be used as standalone tools, they can be combined for a fully digitalized process that further enhances the accuracy and efficiency of your anxiety study.

At Signant, our mission is to help you develop and deliver new treatments or therapies faster in order to improve the quality of life for those living with Generalized Anxiety Disorder.

SIGNANT'S PSYCHIATRY EXPERIENCE BY THE NUMBERS



I - IV
PHASES



500+
STUDIES



21,000+
SITES



17,000+
PATIENTS



60
COUNTRIES



55+
LANGUAGES

DRIVE BETTER ANXIETY RESEARCH OUTCOMES WITH **SIGNANT SMARTSIGNALS SOLUTIONS**

These solutions can be used individually or integrated together for a seamless, end-to-end digital experience.



eCOA

[LEARN MORE →](#)



eCONSENT

[LEARN MORE →](#)



RATER TRAINING
& QUALIFICATION

[LEARN MORE →](#)



PURESIGNAL
ANALYTICS

[LEARN MORE →](#)




SCIENTIFIC
ADVISORY

[LEARN MORE →](#)

DISCUSS YOUR NEXT STUDY WITH US

Our global team of therapeutic area experts advise on all areas of the clinical development process, including:

- Clinical science and medicine
- Data analysis
- Regulatory
- Operations and trial administration
- Global logistics



[MEET THE EXPERTS →](#)